Margaret Tempero, MD

Education
M.D., 1977 - School of Medicine, University of Nebraska
Honors and Awards
  • Editor-In-Chief, Journal Nat'l Comprehensive Cancer Network, 2014-Pres
  • Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF, 2012-Pres
  • Doris and Don Fisher Distinguished Professor in Clinical Research, UCSF, 2000-2012
Websites
Publications

  1. Tempero M, JNCCN Staff. Changes on the Horizon. Journal of the National Comprehensive Cancer Network : JNCCN 2024. PMID: 38503054


  2. Tempero M. A New Beginning. Journal of the National Comprehensive Cancer Network : JNCCN 2024. PMID: 38244270


  3. Tempero M. Letter to Santa. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 38081127


  4. Tempero M. Giving Thanks. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37935094


  5. Tempero M. It Just Keeps Getting Better! Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37856228


  6. Tempero M. Understanding Cancer Risk-Genes Matter! Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37673114


  7. Tempero M. Being Sick Isn't Easy. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37549910


  8. Tempero M. A Glimpse Into the Future. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37433438


  9. Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37433437


  10. Tempero M. "The Times They Are A-Changin' ". Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37308121


  11. Tempero M. Clinical Trials: Does One Size Really Fit All? Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37156480


  12. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023. PMID: 37075273


  13. Tempero M. I'm Getting Better at This! Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37015330


  14. Tempero M. Dying in the Queue and Where Is My Nurse? Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 36898364


  15. Tempero M. Your Words Mean Something! Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 36791761


  16. Tempero M. Another New Beginning. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 36630896


  17. Sinha M, Betts C, Zhang L, Griffith MJ, Solman I, Chen B, Liu E, Tamaki W, Stultz J, Marquez J, Sivagnanam S, Cheung A, Pener D, Fahlman A, Taber E, Lerner K, Crocker M, Todd K, Rajagopalan B, Ware C, Bridge M, Vo J, Dragomanovich H, Sudduth-Klinger J, Vaccaro G, Lopez CD, Tempero M, Coussens LM, Fong L. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. Journal for immunotherapy of cancer 2023. PMID: 36593070


  18. Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M, APACT Investigators. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022. PMID: 36521097


  19. Tempero M. Letter to Santa. Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 36509076


  20. Tempero M. Welcome Aboard! Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 36351337


  21. Seufferlein T, Uhl W, Kornmann M, Alg?l H, Friess H, K?nig A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, Metzger R, Wille K, Gerdes B, Schimanski CC, Graupe F, Kunzmann V, Klein I, Geissler M, Staib L, Waldschmidt D, Bruns C, Wittel U, Fichtner-Feigl S, Daum S, Hinke A, Blome L, Tannapfel A, Kleger A, Berger AW, Kestler AMR, Schuhbaur JS, Perkhofer L, Tempero M, Reinacher-Schick AC, Ettrich TJ. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Annals of oncology : official journal of the European Society for Medical Oncology 2022. PMID: 36209981


  22. Tempero M. We Are Winning This War! Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 36240853


  23. Tempero M. Together Again! Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 36075390


  24. Tempero M. My Report Card. Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35948030


  25. Tempero M. Failure Doesn't Feel Good! Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35830894


  26. Tempero M. I Cannot Afford This! Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35714674


  27. Tempero M. Out in the World Again. Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35545170


  28. Tempero M. It's OK to Share! Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35390764


  29. Walker EJ, Blanco AM, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Pancreas 2022. PMID: 35695740


  30. Tempero M. Getting Complex Therapies to More People: A Vexing Dilemma. Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35276671


  31. Tempero M. News About the Tiny Pharmacists Within Us. Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35130496


  32. Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH. Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis. American journal of clinical oncology 2022. PMID: 34864778


  33. Tempero M. Starting Over, Again! Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 34991069


  34. Tempero M. Thank You, Santa! Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34902827


  35. Sessa C, Cortes J, Conte P, Cardoso F, Choueiri T, Dummer R, Lorusso P, Ottmann O, Ryll B, Mok T, Tempero M, Comis S, Oliva C, Peters S, Tabernero J. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective. ESMO open 2021. PMID: 34953404


  36. Tempero M. Reimagining Professional Meetings: Another Lesson From COVID-19. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34781269


  37. Tempero M. Five Patients and One Important Lesson. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34666311


  38. Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. The oncologist 2021. PMID: 34506673


  39. Tempero M. Targeting KRAS: Good, But Is It Good Enough? Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34551387


  40. Rustgi AK, Hines OJ, Tempero MA, Saluja AK, Habtezion A, Li M, Uc A, Go VLW. Minutes of the Business Meeting of the American Pancreatic Association, Sunday, November 1, 2020, Virtual Meeting. Pancreas 2021. PMID: 34643611


  41. Tempero M. Something to Crow About! Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34416712


  42. Tempero M. Pan-Cancer Screening: A Dream or a Nightmare. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34340210


  43. Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clinical cancer research : an official journal of the American Association for Cancer Research 2021. PMID: 34312215


  44. Tempero M. Informed Consent: Is It Really? Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34214973


  45. Tempero M. Open Notes Are Here: Are We Ready? Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 34794123


  46. Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Annals of surgical oncology 2021. PMID: 33813673


  47. Tempero M. Being Closer to Normal. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 33845458


  48. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 33845462


  49. Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Väyrynen SA, Clancy TE, Rubinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RC, Park BS, Mori M, Nowak JA, Wolpin BM, Coussens LM. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer discovery 2021. PMID: 33727309


  50. Tempero M. It's All About Trust! Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 33668022


  51. Tempero M. Learning From Our Mistakes. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 33545686


  52. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D, Macarulla T. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Annals of oncology : official journal of the European Society for Medical Oncology 2021. PMID: 33539945


  53. Tempero M. New Year's Resolutions - A Different Perspective. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 33406497


  54. Tempero M. Lasting Effects of COVID-19: Reimbursement Reform? Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 33152702


  55. Tempero M. Flirting With Disaster: COVID-19 and Cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 33022645


  56. Tempero M. COVID-19 and Cancer: Unintended Consequences. Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32886904


  57. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. The Journal of clinical investigation 2020. PMID: 32749238


  58. Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ, HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020. PMID: 32706635


  59. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular therapy : the journal of the American Society of Gene Therapy 2020. PMID: 32730744


  60. Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR. American journal of roentgenology 2020. PMID: 32755156


  61. Tempero M. I Can't Breathe! Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32634769


  62. Hafez N, Rugo HS, Tempero MA, Fox E, Reaman GH, Lyerly HK, Walker D, LoRusso PM. Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32571790


  63. Tempero M. My Two-Dimensional Life. Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32502979


  64. Tempero M. Lessons From a Tiny Strand of RNA. Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32380459


  65. Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, Coussens LM, Jaffee EM, Le DT. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32273276


  66. Tempero M. Health and the Gut Microbiome: Who Knew? Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32259784


  67. Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas 2020. PMID: 32132518


  68. Tempero M. Taking Our Hands Off the Wheel. Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32135519


  69. Tempero M. It's About Time! Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 32023523


  70. Tempero M. This Time I Mean It! Journal of the National Comprehensive Cancer Network : JNCCN 2020. PMID: 31910382


  71. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. American journal of clinical oncology 2019. PMID: 31634155


  72. Tempero M. Santa, Can You Hear Me? Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31805531


  73. Tempero M. Giving Thanks. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31693979


  74. Tempero M. My Summer Vacation. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31590150


  75. Tempero M. We All Own This! Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31487675


  76. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019. PMID: 31381464


  77. Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Pancreas 2019. PMID: 31268983


  78. Tempero M. Managing Expectations. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31390589


  79. Tempero M. Taking the Mountain to Muhammad. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31319392


  80. Tempero M. Tackling Cost: A Prescription for Spending Wisely. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31200360


  81. Tempero M. Finding Room for Success. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31085761


  82. Tempero MA. NCCN Guidelines Updates: Pancreatic Cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 31117041


  83. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Familial cancer 2019. PMID: 30267352


  84. Tempero M. The Time Has Come! Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 30959464


  85. Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? The American journal of surgical pathology 2019. PMID: 30211728


  86. Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 30865919


  87. Tempero M. Kids, There's an App for That! Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 30787121


  88. Tempero M. New Year, New Look! Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 30659122


  89. Tempero M. An Oncologist's Letter to Santa: Bring Me Drugs! Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 30545986


  90. Tempero M. I'm Conflicted. Are You? Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 30442729


  91. Tempero M. One Size Fits All? Really? Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 30323084


  92. Tempero M. Getting What You Pay For: Finding Value in Cancer Care. Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 30181413


  93. Tempero M. Notes From the Other Side. Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 30099366


  94. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR. American journal of roentgenology 2018. PMID: 30063366


  95. Tempero M. Genomic Medicine Takes the Stage, Again! Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 30006420


  96. Tempero M. Movin' On Up! Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 29891517


  97. Tempero M. Getting Into the Weeds. Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 29752317


  98. Tempero M. Standing Together or Alone. Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 29632051


  99. Tempero M. Molecular Diagnostics: Another Battle Brewing. Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 29523658


  100. Tempero M. Extending Our Reach-Will Telemedicine Get Us There? Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 29439170


  101. Tempero M. Revisiting New Year's Resolutions. Journal of the National Comprehensive Cancer Network : JNCCN 2018. PMID: 29295874


  102. Tempero M. It's About Time! Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 29223979


  103. Tempero MA. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Cancer journal (Sudbury, Mass.) 2017. PMID: 29189324


  104. Tempero M. Who's Watching the Kids? Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 29118220


  105. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget 2017. PMID: 29228650


  106. Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future oncology (London, England) 2017. PMID: 29235360


  107. Tempero M. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28982741


  108. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. The oncologist 2017. PMID: 28935773


  109. Tempero M. Your Genes: Getting the Best Fit. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28874592


  110. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28784865


  111. Tempero M. When It's Really Good, We Know It! Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28784856


  112. Tempero M. Reducing the Cost of Cancer Care: When Less Is More. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28687571


  113. Tempero M. Getting Practical About Recertification. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28596253


  114. Tempero M. Active Systemic Treatment of Pancreatic Cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28515255


  115. Tempero M. Hospice: Angels at Work. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28476733


  116. Tempero M. Politics as Usual-Not! Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28404753


  117. Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute 2017. PMID: 28376157


  118. Tempero M. Saying Yes. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28275029


  119. Tempero M. Mad About MACRA. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28188184


  120. Tempero M. New Year's Resolutions. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28040714


  121. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing Researcher Needs for a Virtual Biobank. Biopreservation and biobanking 2016. PMID: 27929677


  122. Tempero M. An Oncologist's Letter to Santa. Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27956532


  123. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA, Australian Pancreatic Cancer Genome Initiative, Hofmann O, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Gill AJ, Pearson JV, Grimmond SM, Waddell N, Biankin AV. Hypermutation In Pancreatic Cancer. Gastroenterology 2016. PMID: 27856273


  124. Tempero M. My Knee Hurts! Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27799504


  125. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas 2016. PMID: 27171514


  126. Tempero M. Crossing the Line. Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27697973


  127. Tempero M. Hillary and Donald, Our Patients Are Watching. Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27587617


  128. Tempero M. I'll Have Another Shot, Please! Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27496107


  129. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Journal of surgical oncology 2016. PMID: 27444658


  130. Tempero M. The Greatest Show on Earth! Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27407120


  131. Tempero M. Did the IRB Approve This? Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27283161


  132. Tempero M. Closely Guarded Secrets. Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27160226


  133. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nature reviews. Disease primers 2016. PMID: 27158978


  134. Tempero M. Letting Nature Loose. Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 27059185


  135. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas 2016. PMID: 26390428


  136. Tempero M. Promising the Moon! Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 26957609


  137. Tempero M. Put Us Out of Business--Please! Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 26850482


  138. Tempero M. Bringing Biosimilars to the Clinic: What's the Fuss? Journal of the National Comprehensive Cancer Network : JNCCN 2016. PMID: 26733549


  139. Tempero M. Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Journal of oncology practice 2016. PMID: 26759462


  140. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer discovery 2015. PMID: 26715645


  141. Tempero M. Paying Less for High-Value Care--Are You Kidding Me? Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 26656513


  142. Tempero M. At Last: Getting Paid to Think! Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 26553759


  143. Tempero M. Putting an End to It! Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 26483055


  144. Tempero M. Crossing Over. Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 26358787


  145. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2015. PMID: 26251290


  146. Tempero M. Move It! Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 26285237


  147. Tempero M. Express Scripts? Really? Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 26150575


  148. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer discovery 2015. PMID: 26109333


  149. Tempero M. Improving Access to Drugs--Big Pharma Comes to the Table. Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 26085384


  150. Tempero MA. Multidisciplinary management of pancreatic cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 25995435


  151. Tempero M. Reducing costs by changing behavior-really? Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 25964633


  152. Tempero M. Turf war over diagnostic testing. Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 25870372


  153. Tempero M. Putting precision medicine on the national agenda. Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 25736000


  154. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Australian Pancreatic Cancer Genome Initiative, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015. PMID: 25719666


  155. Tempero M. All bundled up! Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 25691601


  156. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A, American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015. PMID: 25605844


  157. Tempero M. Meet the New JNCCN! Journal of the National Comprehensive Cancer Network : JNCCN 2015. PMID: 25583762


  158. Tempero M. Happy anniversary! Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 25505204


  159. Tempero M. Bringing science to clinical practice. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 25361794


  160. Tempero M. Cancer screening: when is the juice worth the squeeze? Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 25313175


  161. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR in biomedicine 2014. PMID: 25199993


  162. Tempero M. Getting what you pay for: finding value in cancer care. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 25190688


  163. Tempero M. Incentive-based oncology: unintended consequences? Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 25099438


  164. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 25099441


  165. Tempero M. A publicly funded clinical trials network: do we need it? Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 24994914


  166. Tempero M. Embracing team-based oncology care. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 24925194


  167. Tempero M. Managing the fruits of our success. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 24812128


  168. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 2014. PMID: 24622062


  169. Tempero M. The changing face of community practice: the new normal. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 24717562


  170. Tempero M. JNCCN going forward. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 24616533


  171. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British journal of cancer 2013. PMID: 24022191


  172. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British journal of cancer 2013. PMID: 23880820


  173. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013. PMID: 23622141


  174. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013. PMID: 23669224


  175. Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013. PMID: 23344262


  176. Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer journal (Sudbury, Mass.) 2012. PMID: 23187854


  177. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Australian Pancreatic Cancer Genome Initiative, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012. PMID: 23103869


  178. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. American journal of clinical oncology 2012. PMID: 21552099


  179. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer chemotherapy and pharmacology 2012. PMID: 23053263


  180. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA, National Comprehensive Cancer Networks. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2012. PMID: 22679115


  181. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature medicine 2011. PMID: 21460848


  182. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Annals of oncology : official journal of the European Society for Medical Oncology 2011. PMID: 21199884


  183. Collisson E, Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2010. PMID: 21106729


  184. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA, NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2010. PMID: 20876541


  185. International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cros A, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, Eshleman JR, Etemadmoghadam D, Gardiner BB, Gardiner BA, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van't Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, Piris MA, Montserrat E, González-Díaz M, Puente XS, Jares P, Valencia A, Himmelbauer H, Himmelbaue H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van't Veer L, et al. International network of cancer genome projects. Nature 2010. PMID: 20393554


  186. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer chemotherapy and pharmacology 2010. PMID: 20130876


  187. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009. PMID: 19858397


  188. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009. PMID: 19858396


  189. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology 2008. PMID: 19041649


  191. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Annals of oncology : official journal of the European Society for Medical Oncology 2008. PMID: 18539618


  192. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Investigational new drugs 2008. PMID: 18379729


  193. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer investigation 2008. PMID: 18181045


  194. Tempero MA. How I treat pancreatic ductal adenocarcinoma. Journal of oncology practice 2008. PMID: 20859443


  195. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2007. PMID: 18053426


  196. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Annals of oncology : official journal of the European Society for Medical Oncology 2007. PMID: 17600091


  197. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics 2007. PMID: 17363191


  198. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A, Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer biomarkers : section A of Disease markers 2007. PMID: 17655039


  199. Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Investigational new drugs 2006. PMID: 16957834


  200. Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer research 2006. PMID: 16397208


  201. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16344320


  202. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Seminars in radiation oncology 2005. PMID: 16183478


  203. Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA, National Comprehensive Cancer Network. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2005. PMID: 16194453


  204. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2005. PMID: 16194454


  205. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer 2005. PMID: 15999098


  206. Tempero MA. Clinical oncology 2004: the president's report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004. PMID: 15542796


  207. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003. PMID: 12885837


  208. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. International journal of gastrointestinal cancer 2003. PMID: 15361643


  209. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2002. PMID: 12243499


  210. Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002. PMID: 12097469


  211. Ko AH, Tempero MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Current oncology reports 2002. PMID: 11937010


  212. Copur MS, Capadano M, Lynch J, Goertzen T, McCowan T, Brand R, Tempero M. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001. PMID: 11331319


  213. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2000. PMID: 10955789


  214. Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M, Leichner P, Lynch JC, Goldenberg D, Armitage JO. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leukemia & lymphoma 2000. PMID: 10811451


  215. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2000. PMID: 10690517


  216. Gwilt P, Tempero M, Kremer A, Connolly M, Ding C. Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil. Cancer chemotherapy and pharmacology 2000. PMID: 10663643


  218. Brand RE, Tempero MA. Pancreatic cancer. Current opinion in oncology 1998. PMID: 9702405


  219. Tempero MA, Brand R. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1998. PMID: 9576306


  220. Habbe TG, McCowan TC, Goertzen TC, Leveen RF, Culp WC, Tempero MA. Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. Journal of vascular and interventional radiology : JVIR 1998. PMID: 9540905


  221. Tempero M. Biologic therapy of gastrointestinal cancer. Cancer treatment and research 1998. PMID: 10326671


  222. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlam J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997. PMID: 9193348


  223. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997. PMID: 9098192


  224. Tempero MA. Walking a difficult path is easier with a friend. Thoughts from a practicing oncologist. Annals of the New York Academy of Sciences 1997. PMID: 9103574


  226. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, Colcher D. Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. Journal of clinical immunology 1997. PMID: 9049790


  227. Engstrom PF, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J, Roh M, Tempero M. NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park, N.Y.) 1996. PMID: 8953601


  228. Haga Y, Tempero MA, Zetterman RK. Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. Biochimica et biophysica acta 1996. PMID: 8876628


  230. Haga Y, Tempero MA, Zetterman RK. Unconjugated bilirubin inhibits in vitro major histocompatibility complex-unrestricted cytotoxicity of human lymphocytes. Biochimica et biophysica acta 1996. PMID: 8634340


  231. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK. Radiolabeled iododeoxyuridine: safety evaluation. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996. PMID: 8676196


  232. Sivinski CL, Lindner DJ, Borden EC, Tempero MA. Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons. Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995. PMID: 8770771


  233. Tempero M, Brand R, Holdeman K, Matamoros A. New imaging techniques in colorectal cancer. Seminars in oncology 1995. PMID: 7570057


  234. Harrison KA, Tempero MA. Diagnostic use of radiolabeled antibodies for cancer. Oncology (Williston Park, N.Y.) 1995. PMID: 8924373


  235. Tan-Shalaby J, Tempero M. Malignancies after liver transplantation: a comparative review. Seminars in liver disease 1995. PMID: 7660168


  236. Kessinger A, Bishop MR, Anderson JR, Armitage JO, Bierman PJ, Reed EC, Tarantolo S, Tempero MA, Vose JM, Warkentin PI. Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization. Journal of hematotherapy 1995. PMID: 7543352


  237. Tempero MA, Haga Y, Sivinski C, Birt D, Klassen L, Thiele G. Immunologic effects of levamisole in mice and humans: evidence for augmented antibody response without modulation of cellular cytotoxicity. Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995. PMID: 7728305


  238. Kornbrot B, Kobayashi RH, Singer A, Tempero MA, Heiner DC. Hypersensitivity to therapeutic murine monoclonal antibodies. The Nebraska medical journal 1994. PMID: 7870212


  239. Tempero M, Anderson J. Progress in colon cancer: do molecular markers matter? The New England journal of medicine 1994. PMID: 8015575


  240. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. The effect of garlic extract on human metabolism of acetaminophen. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1994. PMID: 8049637


  241. Haga Y, Sivinski CL, Woo D, Tempero MA. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. International journal of pancreatology : official journal of the International Association of Pancreatology 1994. PMID: 8195641


  242. Tempero M, Colcher D, Dalrymple G, Harrison K, Holdeman K, Joshi S, Quadri S, Linder J, Augustine S, Reed E. Cancer therapy using radioimmunoconjugates. Implications for breast cancer. Annals of the New York Academy of Sciences 1993. PMID: 8279780


  243. Tempero M. Pitfalls in antibody imaging in colorectal cancer. Cancer 1993. PMID: 8508387


  246. Haga Y, Tempero MA, Kay HD, Zetterman RK. Characterization of bilirubin transport system by human peripheral blood mononuclear cells. Journal of leukocyte biology 1992. PMID: 1740642


  247. Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG. Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-A fragments. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 1992. PMID: 1411138


  248. Tempero MA. Progress in chemoprevention of gastrointestinal cancers. Current opinion in oncology 1991. PMID: 1834193


  249. Egami H, Tomioka T, Tempero M, Kay D, Pour PM. Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters. The American journal of pathology 1991. PMID: 2000935


  250. Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, Pour P. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma. International journal of pancreatology : official journal of the International Association of Pancreatology 1991. PMID: 1744438


  251. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990. PMID: 2121912


  252. Tempero MA. Advances in the medical management of advanced gastrointestinal cancers. Current opinion in oncology 1990. PMID: 2095882


  253. Tempero MA, Nishioka K, Knott K, Zetterman RK. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer research 1989. PMID: 2507137


  254. Takiyama Y, Tempero MA, Takasaki H, Onda M, Tsuchiya R, Büchler M, Ness M, Colcher D, Schlom J, Pour PM. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. Human pathology 1989. PMID: 2673979


  255. Wettendorff M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A. Proceedings of the National Academy of Sciences of the United States of America 1989. PMID: 2786203


  256. Tempero M, Takasaki H, Uchida E, Takiyama Y, Colcher D, Metzgar RS, Pour PM. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma. The American journal of surgical pathology 1989. PMID: 2699170


  257. Takasaki H, Tempero MA, Uchida E, Büchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J, Pour PM. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. International journal of cancer 1988. PMID: 3053465


  258. Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, Steplewski Z. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer research 1988. PMID: 3166398


  259. Ness MJ, Pour PM, Tempero MA, Linder J. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1988. PMID: 2467286


  260. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer research 1988. PMID: 3162196


  261. Tempero MA, Knott KK, Zetterman RK. Relationship of dietary cholesterol and cellulose in the prevention of colon cancer. Cancer detection and prevention 1988. PMID: 3224345


  262. Tempero MA, Zetterman RK. Effects of sodium cholate on experimental carcinogenesis and cell proliferation in an excluded colonic segment. Journal of surgical oncology 1987. PMID: 3695530


  263. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer research 1987. PMID: 3308077


  264. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue. International journal of pancreatology : official journal of the International Association of Pancreatology 1987. PMID: 3320227


  265. Uchida E, Tempero MA, Burnett DA, Steplewski Z, Pour PM. Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc 1987. PMID: 3319143


  266. Petrie HT, Klassen LW, Tempero MA, Kay HD. In vitro regulation of human lymphocyte proliferation by selenium. Biological trace element research 1986. PMID: 24254509


  267. Tempero MA, Deschner EE, Zedeck MS. The effect of selenium on cell proliferation in liver and colon. Biological trace element research 1986. PMID: 24254361


  268. Herlyn D, Sears H, Iliopoulos D, Lubeck M, Douillard JY, Sindelar W, Tempero M, Mellstedt H, Maher M, Koprowski H. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma 1986. PMID: 3488951


  269. Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma 1986. PMID: 3744378


  270. Tempero MA, Williams CA, Anderson JC. The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986. PMID: 3522817


  271. Thompson JS, Tempero MA, Haun JL, Vanderhoof JA. The importance of luminal factors in neomucosal growth. The Journal of surgical research 1986. PMID: 3945070


  272. Tempero M. Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. Digestive diseases (Basel, Switzerland) 1986. PMID: 3545561


  273. Berg AR, Linder J, Anderson RW, Tempero MA, Edney JA, Armitage JO. The undifferentiated malignant neoplasm. Identification of lymphoma arising in skeletal muscle by immunohistochemical analysis. JAMA 1985. PMID: 2414476


  275. Tempero MA, Jacobs MM, Lynch HT, Graham CL, Blotcky AJ. Serum and hair selenium levels in hereditary nonpolyposis colorectal cancer. Biological trace element research 1984. PMID: 24263746


  276. Tempero MA, Kessinger A. Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma. Journal of surgical oncology 1982. PMID: 6813600


  277. Tempero MA, Petersen RJ, Zetterman RK, Lemon HM, Gurney J. Detection of metastatic liver disease. Use of liver scans and biochemical liver tests. JAMA 1982. PMID: 7109154


  278. Tempero MA, Smith PW. Disseminated Mycobacterium kansasii presenting with skin lesions in a patient with chronic lymphocytic leukemia. Medical and pediatric oncology 1981. PMID: 7242466


  279. Tempero M, Kessinger A, Lemon HM. VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy. Cancer clinical trials 1981. PMID: 6265110